NG11-2 Phase Ib clinical study in oral mucositis: UK MHRA confirms Scientific Advisory review meeting for June with feedback in late July 2025
Feedback will clarify the development and approval path for NG11-2 in prevention/reduction of radiation-induced oral mucositis in patients with head & neck cancer.
28th -April- 2025
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly cost-effective therapies for the prevention/reduction of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that, after the successful completion of its NG11-2 Phase Ib trial, UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the company’s request for the post-study Scientific Advisory review meeting. It has confirmed that the review will be in June so a written response can be expected in late July 2025.
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
“We are delighted to receive the confirmation of the Scientific Advisory review meeting from the MHRA. We appreciate the opportunity to discuss the NG11-2 Phase Ib trial results, discuss its further development and the roadmap to market, so that NG11-2 can reach the patients-in-need as soon as possible.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Gary Bower, COO
gary.bower@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.